Myoinositol – new possibility in treatment of polycystic ovary syndrome

Czech version

Authors: Tomáš Fait
Authors‘ workplace: Gynekologicko-porodnická klinika 1. lékařské fakulty UK a VFN v Praze, přednosta prof. MUDr. Alois Martan, DrSc.
Published in: Prakt Gyn 2013; 17(2): 129-134
Category: Gynecology and Obstetrics: Review Article

Overview

Myoinositol is an insulin sensitizing agent. It is used in the management of polycystic ovary syndrome. It ameliorates the metabolit profile. It improves quality and quantity of oocytes in women with PSOS. Hirsutism and acne are reduced by myoinositol.

Key words:
anovulation hyperandrogenic cutaneous disorders – hyperinsulinemia – Inofolic^® – myoinositol – polycystic ovary syndrome

Sources

1. Vrbíková J. Syndrom PCO. Interní Med 2003; 5(11): 554–557.

2. Norman FJ, Wu R, Stankiewicz MT. Polycystic ovary syndrome. Med J Aust 2004; 180(3):132–137.

3. Fauser BCJM, Tarlatzis BC, Rebar RW et al (the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group). Consensus on women’s health aspects of polycystic ovary syndrome. Fertil Steril 2012; 97(1): 28–38.

4. Cibula D, Henzl MR, Živný J et al. Základy gynekologické endokrinologie. Grada Publishing: Praha 2002. ISBN 80–247–0236–3.

5. Alpañés M, Fernandez-Durán E, Escobar-Morreale HF. Androgens and polycystic ovary syndrome. Expert Rev Endocrinol Metab 2012; 7(1): 91–102.

6. Minárik J. Novinky v managementu neplodnosti v běžné gynekologické praxi. Význam inositolu. NEUM 2012; 1–2: 13–23.

7. Legro RS, Barnhart HX,Schlaff WD. Clomifene, metformin or both for infertility in the PCOS. N Engl J Med 2007; 356(6): 551–566.

8. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010; 8(2): 127–136.

9. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med 2010; 16(11–12): 543–551.

10. Carlomagno G. Inositol Safety. Eur Rev Med Pharmacol Sci 2011; 15(8): 931–936.

11. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24(3): 139–144.

12. Papaleo E, Unfer V, Baillargeon J-P et al. Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol Endocrinol 2007; 23(12): 700–703.

13. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13(2): 105–110.

14. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agent salone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010; 26(4): 275–280.

15. Papaleo E. Addition of myo‑inositol to clomiphene citrate in PCOS patients clomiphene‑resistant for ovulation induction. Human Reprod 2009; 24(Suppl I): i73-i74. Dostupné z DOI: <http:// doi: 10.1093/humrep/dep746>.

16. Gerli S. Randomised, double blind placebo – controlled trial. Eur Rev Med Pharmacol Sci 2007; 11(5): 347–354.

17. Zacché MM, Caputo L, Filippis S. et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25(8): 508–513.

18. Ciotta L, Stracquadanio M, Pagano I. et al. Effects of myo-inositol supplementation on oocyte´s quality in PCO patiens: a double blind trial. Eur Rev Med Pharmacolo Sci 2011; 15(5): 509–514.

19. Papaleo E, Unfer V, Baillargeon JP. et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91(5): 1750–1754.

20. Minozzi M, Constantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrin 2011; 27(11): 920–924.

21. D´Anna R, Di Benedetto V, Rizzo P et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012; 28(6): 440–442.

22. Fait T, Slíva J et al. Volně prodejné přípravky v gynekologii. Maxdorf: Praha 2011.